摘要
肢端肥大症是一种隐袭起病、缓慢进展的内分泌疾病。肢端肥大症主要由生长激素垂体瘤引起,这种垂体瘤长期、过度分泌生长激素导致循环胰岛素样生长因子-1(insulin-like growth factor-1,IGF-1)升高,从而导致靶器官受损、增加患者死亡率并且降低生活质量。本文检索5年来的相关文献,回顾肢端肥大症的药物治疗进展。
Acromegaly is mostly caused by a pituitary adenoma secreting growth hormone（ GH）,which leads to a wide range of endocrine morbidities,with an insidious onset and slow progression. A long-term overproduction of GH results in elevated insulin-like growth factor-1（ IGF-1）level,which in turn,would cause target organ damage and an increased risk for mortality and decreased quality of life. Herein,the literature regarding the progress of drug therapy for acromegaly in recent five years is reviewed.
出处
《中国生化药物杂志》
CAS
2015年第11期185-188,共4页
Chinese Journal of Biochemical Pharmaceutics
基金
复旦大学附属上海市第五人民医院院级课题(2010YJ05)
